Oncology and Hematology - Global Oncology Academy

Episodes 1-16 of 402

Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Global Oncology Academy
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
- William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Global Oncology Academy
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
- William Oh, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
- George Laliotis, MD, MPH, MHA
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®
TIL^plus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Global Oncology Academy
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
- Jacob Sands, MD
- Elaine Shum, MD
- Estelamari Rodriguez, MD, MPH

Prev
1
2
3
…
25
26
Next

1/6